- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03728712
Evaluation of Ventilation Homogeneity as a Marker of Small Airway Disease in Active Smokers
Quantitative Ventilation Lung Single-photon Emission Computed Tomography With CT Scan (Technegas SPECT/CT) to Assess Early Small Airway Disease in Smokers: a Pilot Study
Ventilation heterogeneity is a hallmark feature of most obstructive pulmonary diseases. In particular, chronic obstructive pulmonary disease (COPD) is pathologically and physiologically characterized by small airway destruction and marked airway cellular inflammation, which result in prominent expiratory airflow limitation, air trapping, hyperinflation and abnormal gas exchange. COPD is strongly linked with the exposition to inhaled irritants, most notably tobacco smoke, and is as such a potentially preventable disease. COPD-related morbidity, mortality and social costs are high: in Canada, COPD is the main cause of hospital admission among all chronic diseases and is the fourth leading cause of death.
Diagnosis of COPD requires the objective demonstration of expiratory airflow limitation using spirometry. In the right clinical context, a post-bronchodilator forced vital capacity (FVC) / forced expiratory volume in 1 second (FEV1) ratio <0.70 is considered indicative of the presence of COPD, and therefore pulmonary function testing is required to make the diagnosis. However, the natural history of COPD represents a slowly-progressive continuum: active smokers that do not meet the criteria for COPD are still at risk of developing the disease. In fact, when compared to healthy non-smokers, active smokers without overt COPD can already show some pathological and clinical features of the disease. Notably, they report increased levels of resting dyspnea, chronic cough, lower exercise capacity, exercise-induced dynamic hyperinflation and marked airway inflammatory cellular infiltration, while conserving normal pulmonary function test values.
These findings highlight the negative, clinically-measurable effects of tobacco smoking on pulmonary function, but also the limitations of standard pulmonary function testing in identifying the presence of early, mild airway disease and quantifying physiological limitations in these subjects. As such, there is a need for a novel, simple and reliable method of quantifying airway disease in this population.
Quantitative lung ventilation single-photon emission computed tomography (SPECT) allows an objective quantification of the regional heterogeneity of ventilation in humans. The coefficient of variation (CV) of the distribution of a radioactive tracer, inhaled during the test, allows the generation of heterogeneity maps and density curves of small elements of the lung. These variables are sensitive to the presence of COPD, asthma, air trapping and are correlated to even slight anomalies in pulmonary function testing in otherwise healthy subjects. As such, SPECT could prove useful as an early marker of airway disease in active smokers at risk of developing COPD, but its use in this context has never been formally tested.
This pilot study addresses the question of whether lung SPECT could provide clinically relevant information on airway disease in active smokers without overt lung disease on pulmonary lung function testing.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 3E4
- Centre Hospitalier de l'Universite de Montreal (CHUM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
For Smokers group:
Inclusion Criteria:
- Active tobacco smoking of at least 10 cigarettes/day AND total smoking history of at least 15 pack-years.
- Normal lung function testing, defined as: FVC/FEV1 ratio, FEV1 and FVC all greater than the lower limit of normal; mean forced expiratory flow at 25 to 75% of CVF (FEF25-75%) >80% of predicted value and absence of concavity on the forced expiratory flow curve, as evaluated by a trained respirologist; total lung capacity (TLC) greater than the lower limit of normal; residual volume (RV), functional residual capacity (FRC), expiratory reserve volume (ERV), inspiratory capacity (IC) and VR/TLC ratio all >80% predicted value and diffusion capacity of the lung for carbon monoxide (DLCO) >80% predicted value when corrected for hemoglobin level.
- Body mass index (BMI) <30 kg/m2
Exclusion criteria:
• Post-bronchodilator change in FEV1 and FVC of more than 6% and/or 100 ml.
For Non-smokers group:
Inclusion Criteria:
- No history of tobacco-smoking.
- Normal lung function testing, defined as: FVC/FEV1 ratio, FEV1 and FVC all greater than the lower limit of normal; mean forced expiratory flow at 25 to 75% of CVF (FEF25-75%) >80% of predicted value and absence of concavity on the forced expiratory flow curve, as evaluated by a trained respirologist; total lung capacity (TLC) greater than the lower limit of normal; residual volume (RV), functional residual capacity (FRC), expiratory reserve volume (ERV), inspiratory capacity (IC) and VR/TLC ratio all >80% predicted value and diffusion capacity of the lung for carbon monoxide (DLCO) >80% predicted value when corrected for hemoglobin level.
- Body mass index (BMI) <30 kg/m2
Exclusion criteria:
• Post-bronchodilator change in FEV1 and FVC of more than 6% and/or 100 ml.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Never smokers
Participants with no history of cigarette smoking
|
Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours. Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation. |
Active smokers
Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
|
Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours. Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC-CV>20% values
Time Frame: Immediately after data acquisition
|
Density curves with coefficient values >20% will be compared among the two groups of participants
|
Immediately after data acquisition
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship between AUC-CV>20% values and lung function data
Time Frame: Immediately after data acquisition
|
Correlation between AUC-CV>20% values and forced expiratory volume in 1 second, forced vital capacity, residual volume, lung clearance index and diffusion capacity for carbon monoxide
|
Immediately after data acquisition
|
Relationship between AUC-CV>20% values and clinical symptoms
Time Frame: Immediately after data acquisition
|
Correlation between AUC-CV>20% values and dyspnea severity (modified medical research council scale) and respiratory symptoms (COPD assessment test)
|
Immediately after data acquisition
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Bruno-Pierre Dubé, MD, Centre Hospitalier de l'Universite de Montreal (CHUM)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18.149
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cigarette Smoking
-
Maastricht University Medical CenterCompletedCigarette Smoking | Cigarette Smoking Toxicity | Smoking BehaviorNetherlands
-
Duke UniversityGeorgetown University; University of MichiganWithdrawnSmoking | Cigarette Smoking | E-cigarette Use
-
Assistance Publique - Hôpitaux de ParisUnknownSmoking Cessation | Smoking, Cigarette | Electronic CigaretteFrance
-
Yale UniversityNational Cancer Institute (NCI)RecruitingSmoking Cessation | Cigarette Smoking | E-Cigarette UseUnited States
-
Medical University of South CarolinaAmerican Cancer Society, Inc.RecruitingSmoking Cessation | Electronic Cigarette Use | Cigarette SmokingUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); New York University; Stanford UniversityRecruitingSmoking | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of St AndrewsNational Health Service, United KingdomUnknownSmoking | Cigarette Smoking | Smoking, Tobacco
-
BIDI VaporCompletedCigarette Smoking | E-cigarette UsePoland
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
Clinical Trials on SPECT/CT
-
Yale UniversityUniversity of Illinois at Urbana-ChampaignRecruitingDiabetes Mellitus | Peripheral Arterial DiseaseUnited States
-
Rambam Health Care CampusCompleted
-
Central Hospital, Nancy, FranceCompleted
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityCompletedBreast Cancer FemaleRussian Federation
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaTerminated
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Rambam Health Care CampusCompleted
-
Martini Hospital GroningenRecruitingOsteoarthritis | Osteoarthritis AnkleNetherlands
-
Mayo ClinicRecruitingFocus of Study is Comparison of 2 Types of Gamma CamerasUnited States
-
University of California, San FranciscoCompletedFeasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer PatientsProstate CancerUnited States